89bio
ETNB
ETNB was delisted on the 29th of October, 2025.
34 hedge funds and large institutions have $275M invested in 89bio in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
75.72% more ownership
Funds ownership: 0% → 75.72% (+76%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$111M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$88M |
| 3 |
VMI
VHCP Management III
New York
|
+$26.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.74M |
Top Sellers
ETNB Hedge Fund Activity: Q4 2019 in Review
34 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q4 2019, worth a combined $275M.
Buyers outnumbered sellers: 34 funds opened new ETNB positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $111M.
- 34 institutional investors held 89bio (ETNB) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $275M of 89bio stock for Q4 2019.
- 34 funds opened new 89bio positions in Q4 2019 and 0 closed out, a net change of +34 holders.
- The largest 89bio buyer in Q4 2019 was OrbiMed, an estimated $111M added.
Based on aggregated 13F filings for Q4 2019.